

## EIA Summary Report

Name of policy

Telestroke Project Implementation Plan
--

Aim of policy

It defines the scope, approach, outputs, roles and responsibilities required to deliver an out of hours telestroke service in Lancs. and Cumbria.
---

This policy is:

Existing  Proposed

This policy is aimed at:

Staff  Public/Patients

Details of the individuals (include name, job title, dept and base) carrying out the EIA (ensure the lead person is clearly identified)

<p><b>Lead Impact Assessor:</b> , Telestroke Project Manager</p> <p><b>Impact Panel Members:</b></p> <ul style="list-style-type: none"> <li>- A4C Administrator / Interim Head of E&amp;D</li> <li>- Nursing Policy &amp; Practice Development Co-ordinator</li> <li>- Director of IMT</li> </ul>
---

Which groups of people were considered during the assessment that may be affected by the policy?

Staff and patients in all categories of personal characteristics.
---

What impacts did you identify?

<p><b>Positive Impacts</b></p> <p>Minority Ethnic Groups – positive reference</p> <p>Disability – recognition that stroke can lead to disability</p>	<p><b>Negative Impacts</b></p> <p>Possible contradictions in use of thrombolysis in pregnancy.</p> <p>Age restriction in use of Alteplase.</p>
--	--

What information / data / research / evidence was used? Is any additional information / research required?

<p>Information / data / research / evidence used:</p> <p>Project implementation plan</p>	<p>Additional information required:</p> <p>NICE Guidelines on Thrombolysis</p>
--	--

Which Groups / Organisations / Committees / Directorates involved in the policy development?

Medical Directorate, Stroke network, IT dept, Stroke Physicians from Lancs and Cumbria, Radiology and Nursing staff.

Recommendations for Action Plan (see page 4)

Check age restrictions and possible contraindications in maternity.

Lead EIA Signature

Date

Tuesday, 23 November 2010

Monitoring and review dates for assessment

Monitoring Dates:  
1<sup>st</sup> April 2011

Review date  
1<sup>st</sup> April 2012

The Lead Impact Assessor is responsible for forwarding a signed hard copy of the summary report and screening checklist, along with an electronic version, to the Head of Clinical Planning / Equality and Diversity, WCH, for publication on the Website.

**Approved for publication onto Website**

**Interim Head of Clinical Planning/Equality & Diversity**

### EIA Checklist

Groups considered / whether affected		Positive Impact	Negative Impact	None
Minority Ethnic Groups	<input checked="" type="checkbox"/>	Positive reference to higher risk of stroke in certain minorities.		<input type="checkbox"/>
Disability	<input checked="" type="checkbox"/>	Recognition that stroke can lead to disabilities		<input type="checkbox"/>
Gender / Transgender	<input type="checkbox"/>			<input checked="" type="checkbox"/>
Marital status	<input type="checkbox"/>			<input checked="" type="checkbox"/>
Pregnancy and maternity	<input checked="" type="checkbox"/>		There is very limited experience with the use of alteplase during pregnancy and lactation. Studies in animals have shown reproductive toxicity. <sup>1</sup>	<input type="checkbox"/>
Age	<input checked="" type="checkbox"/>		Alteplase is not indicated for the treatment of acute stroke in paediatric patients under 18 years or adults over 80 years of age. <sup>1</sup>	<input type="checkbox"/>
Sexual Orientation	<input type="checkbox"/>			<input checked="" type="checkbox"/>
Religion, Faith and Belief	<input type="checkbox"/>			<input checked="" type="checkbox"/>
Carers	<input type="checkbox"/>			<input checked="" type="checkbox"/>
Socio-Economic status including Rurality	<input checked="" type="checkbox"/>	Improved access to Thrombolysis in rural areas		<input type="checkbox"/>
Human Rights	<input checked="" type="checkbox"/>	Aiming to protect life and improving the quality of patient care		<input type="checkbox"/>
Any other personal characteristic	<input type="checkbox"/>			<input checked="" type="checkbox"/>

<sup>1</sup> <http://www.medicines.org.uk/emc/medicine/308>

## Action Plan

	Recommendation	Action By			Complete
		Name	Title	Date	
1	<p>Check age limitation in the use of Alteplase. Evidence from the manufacturer suggests that in stroke patients the likelihood of good outcomes decreases with increasing age. It is not licensed for children and those under 18. This group argue for the inclusion of patients aged over 80 to receive treatment.</p>		Telestroke Project Manager	1 <sup>st</sup> Dec 2010	
2	<p>Check maternity contraindications. Evidence suggests that there is some reproductive toxicity in animal studies. It would be up to the individual clinician to weigh up the benefits of possibly preventing serious disability through drug administration against possible side effects.</p>		Telestroke Project Manager	1 <sup>st</sup> Dec 2010	
3					
4					
5					